Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 February 2018

  • Email
  • Help

News

23/02/2018

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 February 2018

Five medicines recommended for approval, including two orphans

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended five medicines for approval, including two orphan medicines1, at its February 2018 meeting.

The CHMP recommended granting a marketing authorisation for Amglidia (glibenclamide), for the treatment of neonatal diabetes mellitus in newborns, infants and children. Because neonatal diabetes is a very rare disease, Amglidia was granted an orphan designation. For more information, please see the press release in the grid below.

The cancer medicine Mylotarg (gemtuzumab ozogamicin) received a positive opinion for the treatment of acute myeloid leukaemia in patients aged 15 years and above, giving young patients a new treatment option. Mylotarg has an orphan designation.

The Committee recommended granting a marketing authorisation for Alpivab (peramivir), for the treatment of uncomplicated influenza.

The CHMP granted a positive opinion for two informed consent applications for the maintenance treatment of adult patients with moderate to severe chronic obstructive pulmonary disease: Riarify2 (beclometasone dipropionate anhydrous / formoterol fumarate dihydrate / glycopyrronium) and Trydonis (beclometasone dipropionate anhydrous / formoterol fumarate dihydrate / glycopyrronium).

An informed consent application makes use of data from the dossier of a previously authorised medicine, with the marketing authorisation holder of that medicine giving consent for the use of their data in the application.

Negative opinion on two medicines

The CHMP adopted a negative opinion for Nerlynx (neratinib). Nerlynx was expected to be used to treat breast cancer.

The CHMP also adopted a negative opinion for an extension of therapeutic indication for Sutent (sunitinib).

For more information on these negative opinions, please see the questions-and-answers documents in the grid below.

Six recommendations on extensions of therapeutic indication

The Committee also recommended extensions of indications for Bosulif, Feraccru, Isentress, Kineret, Lynparza and Xgeva.

A press release on the extension of indication for Kineret for the treatment of Still’s disease in children and adults is available in the grid below.

Withdrawal of application

An application to extend the use of Zydelig (idelalisib) for the treatment of chronic lymphocytic leukaemia has been withdrawn. A questions-and-answers document on this withdrawal is available below.

Agenda and minutes

The agenda of the February 2018 meeting is published on EMA’s website. Minutes of the January 2018 CHMP meeting will be published in the coming weeks.

CHMP statistics

Key figures from the February 2018 CHMP meeting are represented in the graphic below.

More information on all other outcomes of the CHMP February 2018 meeting is available in the grid below.


1As always at time of approval, these orphan designations will now be reviewed by EMA’s Committee for Orphan Medicinal Products (COMP) to determine whether the information available to date allows maintaining the medicines’ orphan status and granting the medicines ten years of market exclusivity.

2Previously known as CHF 5993 Chiesi Farmaceutici S.p.A.

 

 CHMP_highlights_February_2018

 Download image in PDF format

 

Positive recommendations on new medicines

Name of medicineAlpivab 
International non-proprietary name (INN)peramivir 
Marketing-authorisation applicantBiocryst UK Limited 
Therapeutic indicationTreatment of uncomplicated influenza 
More informationSummary of opinion for Alpivab

 

Name of medicineAmglidia 
INNglibenclamide 
Marketing-authorisation applicantAmmtek 
Therapeutic indicationTreatment of neonatal diabetes 
More information

Summary of opinion for Amglidia


Press release: First medicine to treat neonatal diabetes

  

Name of medicineMylotarg 
INNgemtuzumab ozogamicin 
Marketing-authorisation applicantPfizer Limited 
Therapeutic indicationTreatment of acute myeloid leukaemia
More informationSummary of opinion for Mylotarg

 

Positive recommendations on new informed-consent applications

Name of medicine Riarify (Previously known as CHF 5993 Chiesi Farmaceutici S.p.A.)
INNbeclometasone dipropionate anhydrous / formoterol fumarate dihydrate / glycopyrronium 
Marketing-authorisation applicantChiesi Farmaceutici S.p.A. 
Therapeutic indicationMaintenance treatment of adult patients with moderate to severe chronic obstructive pulmonary disease
More informationSummary of opinion for Riarify (Updated on 27/02/2018)

 

Name of medicineTrydonis 
INNbeclometasone dipropionate anhydrous / formoterol fumarate dihydrate / glycopyrronium 
Marketing-authorisation applicantChiesi Farmaceutici S.p.A. 
Therapeutic indicationMaintenance treatment of adult patients with moderate to severe chronic obstructive pulmonary disease 
More informationSummary of opinion for Trydonis

 

Negative recommendation on new medicine

Name of medicineNerlynx 
INNneratinib 
Marketing-authorisation applicantPuma Biotechnology Ltd
Therapeutic indicationTreatment of breast cancer 
More informationQuestions and answers on Nerlynx

 

Positive recommendations on extensions of indications 

Name of medicineBosulif
INNbosutinib
Marketing-authorisation holderPfizer Limited
More informationSummary of opinion for Bosulif

 

Name of medicineFeraccru
INNferric maltol 
Marketing-authorisation holderShield TX (UK) Ltd
More informationSummary of opinion for Feraccru

 

Name of medicineIsentress
INNraltegravir 
Marketing-authorisation holderMerck Sharp & Dohme Limited
More informationSummary of opinion for Isentress

 

Name of medicineKineret 
INNanakinra 
Marketing-authorisation holderSwedish Orphan Biovitrum AB (publ)
More information

Summary of opinion for Kineret


Press release: New treatment option for rare inflammatory disease

  

Name of medicineLynparza 
INNolaparib 
Marketing-authorisation holderAstraZeneca AB
More informationSummary of opinion for Lynparza

      

Name of medicineXgeva 
INNdenosumab
Marketing-authorisation holderAmgen Europe B.V.
More informationSummary of opinion for Xgeva

 

Negative recommendation on extension of indication

Name of medicineSutent 
INNsunitinib 
Marketing-authorisation holderPfizer Limited
More informationQuestions and answers on Sutent

 

Withdrawal of application for extension of indication

Name of medicineZydelig 
INNidelalisib 
Marketing-authorisation applicantGilead Sciences International Ltd.
More informationQuestions and answers on Zydelig

 

Other updates

Recommendations on eligibility to PRIME scheme
Scientific advice and protocol assistance
Overview of (invented) names reviewed in January 2018 by the Name Review Group (NRG)

 

How helpful is this page?

Average rating:

 Based on 19 ratings

Add your rating:

See all ratings
3 ratings
3 ratings
3 ratings
4 ratings
6 ratings
    

Tell us more

Related content

Please note that not all documents associated with this page are published at the same time. This page is updated with new documents as soon as they become available. Therefore, users are asked to check the page regularly.

Contact point:

EMA Press office
Tel. +44 (0)20 3660 8427
E-mail: press@ema.europa.eu
Follow us on Twitter @EMA_News